# US 7,612,175 B2 · Scavenger receptor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,612,175 B2
- Document ID: US7612175B2
- Status: Granted
- Kind: B2
- Application number: 11/716,967
- Filed: 2007-03-12
- Published: 2007-09-27
- Granted: 2009-11-03
- Earliest claimed: 2000-02-14
- Assignees: Fuso Pharmaceutical Industries, Ltd.
- Inventors: Nobutaka Wakamiya
- Web page: https://patentgrep.com/patent/US7612175B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/04: Antibacterial agents
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/00: Detection or diagnosis of diseases
- G01N 2800/32: Cardiovascular disorders
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Novel scavenger receptors having an SR structure and a collectin-like structure are provided, which can be utilized in the elucidation of mechanisms of macrophage and basic immunity; in the elucidation of mechanisms of the development of a wide variety of diseases such as arteriosclerosis, diabetic complications and Alzheimer's disease, hyper β-lipoproteinemia, hypercholesterolemia, hypertriglyceridemia, hypo α-lipoproteinemia, transplantation, atherectomy, post angiogenic restenosis, bacterial infections; in the diagnostic, prophylactic and therapeutic methods thereof; and in the development of reagents and drugs for the same. The novel scavenger receptors include proteins comprising an amino acid sequence set out in SEQ ID NO: 2, 4 or 24 or proteins having equivalent properties to the same, or derivatives or fragments thereof as well as isolated polynucleotides comprising a nucleotide sequence encoding these proteins, and related molecules such as antibodies, antagonists and the like. Also disclosed are methods for the treatment using the same.

## Claims

### Claim 1

An isolated and purified polypeptide having an amino acid sequence that comprises amino acid residues 1 to 618 of SEQ ID NO: 24.

### Claim 2 (depends on 1)

An isolated and purified polypeptide according to claim 1, wherein the amino acid sequence of the polypeptide consists of amino acid residues 1 to 618 of SEQ ID NO: 24.

### Claim 3 (depends on 1)

A method for producing the polypeptide according to claim 1 comprising:
culturing in a medium a cell transformed with a polynucleotide that comprises a nucleotide sequence encoding the polypeptide according to claim 1 and collecting the polypeptide produced by the cells.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the cell is an Escherichia coli, an animal or an insect cell.

### Claim 5 (depends on 3)

The method according to claim 3, wherein said polynucleotide is an insert in a vector, and wherein the cell is transformed with the vector.

### Claim 6 (depends on 1)

A method for producing a monoclonal antibody having specificity for the polypeptide according to claim 1, comprising:
(a) administering the polypeptide according to claim 1 to an animal,
(b) selecting the animal that exhibits an antibody titer,
(c) collecting a spleen or a lymph node from the animal,
(d) fusing antibody-producing cells contained therein with myeloma cells, and
(e) selecting a hybridoma cell line that secretes a monoclonal antibody having specificity for the polypeptide of claim 1.

### Claim 7 (depends on 1)

A method for quantitatively determining the polypeptide according to claim 1, comprising:
detecting an immunological binding between the polypeptide according to claim 1 and a monoclonal antibody having specificity for said polypeptide;
quantifying an amount of the polypeptide based on the detected immunological binding.

### Claim 8 (depends on 1)

A method of screening for a drug for treating a pathological state involved in the accumulation of oxidized Low Density Lipoprotein (LDL), wherein the method comprises:
measuring binding between the protein according to claim 1 and oxidized LDL in the presence and absence of a candidate drug, and
identifying a drug for the treatment of a pathological state involved in the accumulation of oxidized LDL by comparing the binding between the protein according to claim 1 and oxidized LDL in the presence and absence of a candidate drug, wherein an inhibitory ability of the candidate drug toward the binding between the protein according to claim 1 and oxidized LDL identifies the candidate drug as a drug for the treatment of the pathological state.

### Claim 9 (depends on 1)

A method of screening for a drug for treating a pathological state involved in the binding of advanced glycation end products (AGE) to cells, comprising:
measuring binding between the protein according to claim 1 and AGE in the presence and absence of a candidate drug, and
identifying a drug for the treatment of a pathological state involved in the binding of AGE to cells by comparing the binding in the presence and absence of a candidate drug, wherein an inhibitory ability of the candidate drug toward the binding between the protein according to claim 1 and AGE identifies the candidate drug as a drug for the treatment of the pathological state.